Sugi Predict

Sugi Predict / Compounds / SCHEMBL30980722

SCHEMBL30980722

SCHEMBL30980722

CC(=O)N[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1c1cc(COCCOCCNC(=O)NCCCC(N)(CCCNC(=O)NCCOCCOCc2cc([C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)on2)CCCNC(=O)NCCOCCOCc2cc([C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)on2)no1

nearest known ligand 0.35

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ OGA O60502 1/20 0.35
▸ MAPK1 P28482 1/20 0.34
▸ MDK P21741 1/20 0.34
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ SLC9A3 P48764 2/20 0.33
▸ LGALS3 P17931 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980574 0.86 HRAS (0.37) OGA
SCHEMBL30980660 0.84 MAPK1 (0.38) MAPK1
SCHEMBL30980633 0.78 LGALS3 (0.38) OGAMAPK1CA12CA1CA2
SCHEMBL30980709 0.78 MAPK1 (0.41) OGAMAPK1MDKLGALS3
SCHEMBL30980522 0.69 MAPK1 (0.43) OGAMAPK1MDKCA1CA2
SCHEMBL30980568 0.67 MAPK1 (0.38) OGAMAPK1MDKLGALS3
SCHEMBL30980642 0.67 MAPK1 (0.43) MAPK1MDKCA1CA2CA9
SCHEMBL18972884 0.67 MAPK1 (0.53) MAPK1MDKCA1CA2CA9
SCHEMBL30980649 0.66 MAPK1 (0.43) MAPK1MDKLGALS3
SCHEMBL30980606 0.66 MAPK1 (0.47) OGAMAPK1MDKCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651902-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
EP-4651901-A1 CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES Lycia Therapeutics, Inc. (US) 2025-11-26 — — EP disclosed
WO-2025035040-A1 LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES LYCIA THERAPEUTICS, INC. (US) 2025-02-13 — — WO disclosed
WO-2024155747-A2 ASGPR BINDING COMPOUNDS AND CONJUGATES LYCIA THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
Send feedback